That country's Food and Drug Administration (FDA) said in its latest Enforcement Report that this was a ‘Class III’ recall, initiated voluntarily by Sun. Such a recall is initiated where “use of or exposure to a violative product is not likely to cause adverse health consequences”.
Class I and II product recalls are far more serious, initiated when there is probability that use or exposure to the product in question can cause temporarily adverse or seriously adverse health consequences.
Drug absorption from a solid dosage depends on release of the drug substance from the product. Pharma companies carry out tests to check drug release characteristics and assess overall product quality.
The tablets were made by Sun at its Halol (Gujarat) unit, alrady under an FDA scanner. After earlier inspections, it had served a warning letter to the company on Halol, last year. The consequential remedial effort has impacted supplies and product approvals from the plant.
The US market contributes half the company’s consolidated revenue. Sun Pharma has since requested the FDA to re-inspect the Halol unit.
“Over the past year, our cGMP (current good manufacturing pratices) capabilities have been strengthened significantly. Talent with long-standing global expertise has enhanced our abilities in this pertinent area. We are also targeting appropriate technology-based solutions to facilitate cGMP compliance, coupled with an increased focus on manpower training,” Sun Pharma managing director Dilip Shanghvi said in his letter to shareholders in the recent annual report. RECENT RECALLS
- Aurobindo Pharma recalled 23,016 bottles of Pantoprazole Sodium delayed-release tablets
- Cadila Healthcare: 2,626 bottles of Bupropion Hydrochloride extended-release tablets
- Sun Pharma: 12,109 bottles of Carvediol tablets
- Lupin: 3,192 bottles of Escitalopram and 26,436 bottles of Lisinopril tablets
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)